| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥74.2B | ¥68.8B | +7.9% |
| Operating Income | ¥8.3B | ¥7.5B | +10.2% |
| Ordinary Income | ¥8.1B | ¥9.9B | -18.3% |
| Net Income | ¥5.8B | ¥6.8B | -13.6% |
| ROE | 10.0% | 12.1% | - |
FY2025 Q3 (9-month cumulative) results: Revenue 74.2B yen (YoY +7.9%), Operating Income 8.3B yen (YoY +10.2%), Ordinary Income 8.1B yen (YoY -18.3%), Net Income 5.8B yen (YoY -13.6%). The company achieved top-line growth and operating profit expansion driven by volume increases across both Biomaterial and Resource Circulation segments. However, ordinary and net income declined due to increased interest expenses from short-term borrowing expansion and one-time gains in the prior year. Operating margin improved to 11.2% from 10.9% YoY, while net margin contracted to 7.9% from 9.9% YoY. Asset efficiency remained at 0.56 turns with ROE at 10.0%. The divergence between operating profit growth and net income decline reflects heightened financial costs and non-operating factors rather than core business deterioration.
Revenue grew 5.4B yen (7.9%) to 74.2B yen, driven by increases across all major revenue categories. Waste disposal and collection services expanded 9.6% to 45.1B yen, constituting 60.8% of total revenue. Product and merchandise sales increased 5.4% to 24.7B yen (33.3% of revenue), while other revenues including recyclable material sales grew 5.9% to 4.4B yen. The Biomaterial segment, which represents the core business at 72.8% of total revenue, expanded sales 8.9% to 54.0B yen with segment profit of 7.3B yen. The Resource Circulation segment grew 10.6% to 12.5B yen with segment profit improving substantially from 0.4B yen to 0.7B yen, indicating improved operational efficiency. Other businesses contributed 7.7B yen in revenue with segment profit turning positive to 0.4B yen from a loss of 0.1B yen in the prior year. Operating profit increased 0.8B yen (10.2%) to 8.3B yen, reflecting operating leverage from revenue growth and controlled SG&A expenses which increased only 6.7% compared to revenue growth of 7.9%. Gross profit margin remained stable at 43.9% versus 44.2% YoY. The gap between operating income growth (10.2%) and ordinary income decline (-18.3%) stems from deterioration in non-operating income, primarily increased interest expense associated with short-term borrowing expansion from 1.3B yen to 2.3B yen (81.1% increase). The prior year included higher non-operating income which did not recur. Net income declined 1.0B yen (-13.6%) to 5.8B yen due to the ordinary income reduction and an effective tax rate of 34.2%. A non-recurring gain of 0.8B yen from fixed asset disposals partially offset the decline. This represents a "revenue up, profit down" pattern at the bottom line, though operating profit followed a "revenue up, profit up" trajectory, indicating core business strength masked by financial structure changes.
The Biomaterial segment generated revenue of 54.0B yen (72.8% of total) with operating profit of 7.3B yen, representing the core business with an operating margin of 13.6%. Segment profit remained nearly flat (declining 0.3% from 7.4B yen), suggesting pricing pressure or cost inflation absorbed within stable absolute profit levels. The Resource Circulation segment contributed revenue of 12.5B yen (16.9% of total) with operating profit of 0.7B yen (margin 5.4%), showing substantial profit improvement from 0.4B yen in the prior year (74.0% increase). This segment demonstrates improving profitability trajectory despite lower margins than the Biomaterial business. Other businesses including environmental logistics, consulting, and security services generated revenue of 7.7B yen (10.4% of total) with operating profit of 0.4B yen (margin 4.6%), recovering from a loss position of negative 0.1B yen in the prior year. The margin differential between segments is material, with Biomaterial achieving 13.6% versus Resource Circulation at 5.4%, reflecting different operational characteristics and capital intensity. Inter-segment eliminations of 0.3B yen were minimal. The Biomaterial segment's dominance in both revenue and profit confirms its position as the primary earnings driver, while Resource Circulation shows operational turnaround potential.
[Profitability] ROE 10.0% compares to industry median of 8.3%, positioning above peer average. Operating margin 11.2% exceeds industry median of 8.2% by 3.0 percentage points, demonstrating strong operational efficiency. Net profit margin 7.9% outperforms industry median of 6.0% by 1.9 percentage points despite non-operating headwinds. Gross margin of 43.9% remained stable YoY. SG&A ratio of 32.7% reflects controlled overhead relative to revenue growth. [Efficiency] Asset turnover 0.56 turns lags industry median of 0.67 turns, reflecting the company's capital-intensive business model with non-current assets representing 81.3% of total assets. Working capital is negative 1.8B yen, indicating aggressive working capital management though inventory turnover improved with stock declining 37.1% YoY. Receivables turnover period and payables turnover require monitoring given industry medians of 61.3 days and 34.7 days respectively. [Financial Health] Equity ratio 44.3% underperforms industry median of 59.2% by 14.9 percentage points, indicating higher leverage. Current ratio 0.58 significantly trails industry median of 2.15x, representing material liquidity constraint. Cash and deposits of 10.5B yen cover only 0.46x of short-term borrowings of 22.7B yen. Interest-bearing debt totals 33.4B yen with short-term debt ratio at 67.1%, creating refinancing risk. Debt-to-equity ratio of 0.57 remains manageable though financial leverage of 2.25x amplifies ROE volatility. [Investment Returns] ROA of 4.4% (calculated as net income 5.8B yen / average assets 132.0B yen) aligns with industry median of 3.9%, though constrained by low asset turnover.
Cash flow statement data is not disclosed for the quarterly period. Balance sheet analysis indicates cash and deposits increased 2.8B yen YoY to 10.5B yen, representing 26.7% growth in cash position. This increase occurred despite net income of 5.8B yen, suggesting cash generation from operations was supplemented by financing activities. Short-term borrowings expanded dramatically by 10.2B yen (81.1%) to 22.7B yen, representing the primary funding source for the period. Long-term loans payable decreased 0.7B yen to 11.1B yen, indicating possible debt restructuring or scheduled repayments. Current liabilities grew 10.7B yen (33.3%) to 42.9B yen, driven predominantly by the short-term borrowing increase. Trade payables increased 0.5B yen (36.1%), reflecting extended payment terms or increased procurement volume. Inventory reduction of 0.2B yen (37.1% decline) released working capital, contributing to liquidity. Accounts receivable remained relatively stable at approximately 11.0B yen. The negative working capital position of negative 1.8B yen combined with short-term debt expansion suggests the company is funding fixed asset investments and operations through short-term credit facilities. The cash-to-short-term-debt coverage ratio of 0.46x indicates limited buffer for debt service without additional refinancing. Non-current assets increased 8.7B yen to 107.5B yen, implying continued capital investment in property, plant and equipment. The financing structure shift toward short-term debt warrants monitoring for rollover risk and interest rate exposure.
Operating income of 8.3B yen compared to ordinary income of 8.1B yen indicates net non-operating expenses of approximately 0.2B yen, representing minimal deviation at 0.3% of revenue. The non-operating expense primarily comprises increased interest costs associated with the 81.1% expansion in short-term borrowings. Financial expenses exceeded financial income, contrasting with the prior year when non-operating income contributed positively. Non-recurring factors include fixed asset disposal gains of 0.8B yen recorded below the ordinary income line, representing 1.0% of revenue and improving net income by approximately 0.5B yen after-tax. This one-time gain partially offset the structural increase in interest burden. The profit before tax of 8.9B yen versus net income of 5.8B yen reflects an effective tax rate of 34.2%, which is elevated compared to standard Japanese corporate rates and warrants attention regarding tax planning efficiency. The divergence between operating profit growth of 10.2% and net income decline of 13.6% is fully attributable to non-operating and tax factors rather than core business deterioration. Operating cash flow data is not disclosed for the quarterly period, preventing direct comparison to net income for accruals assessment. However, the reduction in inventory by 37.1% and stable receivables suggest improving working capital quality. The company did not report any impairment losses or restructuring charges during the period. Earnings quality assessment indicates strong operational earnings with non-operating financial costs and one-time gains creating volatility at the net income level. The recurring earnings power remains sound based on operating profit trajectory.
The company maintains full-year FY2025 guidance of revenue 103.2B yen (YoY +10.0%), operating income 13.0B yen (YoY +13.1%), and ordinary income 13.3B yen (YoY -6.8%). Q3 cumulative progress rates are: revenue 71.9% (74.2B/103.2B), operating income 63.8% (8.3B/13.0B), and ordinary income 60.9% (8.1B/13.3B). Revenue progress of 71.9% exceeds the standard 75% benchmark by negative 3.1 percentage points, indicating slight delay though within normal quarterly variance. Operating income progress of 63.8% trails the 75% benchmark by 11.2 percentage points, suggesting Q4 requires acceleration to 4.7B yen versus Q3 quarterly average of 2.8B yen. This Q4 weighting is substantial but not unprecedented given typical year-end revenue concentration in the waste management and biomaterial industries. Ordinary income progress of 60.9% similarly requires Q4 generation of 5.2B yen to achieve guidance. The forecasted ordinary income decline of 6.8% YoY contrasts with operating income growth of 13.1%, indicating the company anticipates continued non-operating expense pressure from interest costs. The guidance implies Q4 operating margin expansion to approximately 14.5% compared to Q3 cumulative margin of 11.2%, suggesting seasonal profitability improvement or cost reduction initiatives. The company has not revised guidance during the period, maintaining confidence in the original outlook. EPS forecast of 78.22 yen compares to Q3 cumulative EPS of 50.48 yen, implying Q4 EPS of approximately 27.74 yen. Dividend forecast remains 15.00 yen for the full year. No order backlog data is disclosed. Progress rates indicate execution risk for achieving operating and ordinary income targets, requiring monitoring of Q4 performance acceleration and cost control measures.
Annual dividend forecast is 15.00 yen per share for FY2025, compared to prior year dividend information not explicitly disclosed in the provided data. Based on forecast EPS of 78.22 yen, the payout ratio is 19.2% (15.00/78.22), indicating conservative dividend policy with substantial retained earnings. Using Q3 cumulative actual EPS of 50.48 yen and interim dividend of 14.00 yen (annualized assumption), the trailing payout ratio is approximately 55.6% (28.00/50.48), though this calculation may not reflect full-year earnings trajectory. The company maintains a stable dividend policy prioritizing cash preservation. No share buyback activities are disclosed during the period. Total return ratio equals the payout ratio at 19.2% based on forecast figures, suggesting capacity for increased shareholder returns given the low payout level. Dividend per share of 15.00 yen on share price requires market data for yield calculation. The conservative payout ratio of 19.2% provides dividend sustainability buffer and flexibility for growth investment or debt reduction. Given the liquidity constraints indicated by current ratio of 0.58x and cash coverage of short-term debt at 0.46x, the retained earnings allocation toward balance sheet strengthening appears prudent. The company's equity base of 58.7B yen growing from 55.9B yen YoY demonstrates capital accumulation despite profit distribution.
Liquidity and refinancing risk represents the most material concern with current ratio of 0.58x significantly below the industry median of 2.15x and cash coverage of short-term debt at only 0.46x. Short-term borrowings increased 81.1% to 22.7B yen, comprising 67.1% of total interest-bearing debt, creating substantial rollover risk within 12 months. The negative working capital position of negative 1.8B yen combined with current liabilities of 42.9B yen versus current assets of only 24.8B yen necessitates continuous credit facility renewal. Any disruption in bank lending relationships or credit market conditions could impair operational flexibility. Interest rate exposure has materialized with financial costs increasing as short-term borrowings expanded. Given the proportion of debt subject to near-term repricing, a 100 basis point rate increase would add approximately 0.2B yen in annual interest expense, representing 3.4% of operating income. The company's interest coverage ratio (operating income/interest expense, estimated interest expense approximately 0.5-0.7B yen based on ordinary vs operating income gap) remains adequate but vulnerable to margin compression or rate increases. Asset intensity and capital efficiency constraints are evidenced by asset turnover of 0.56x lagging the industry median of 0.67x, with non-current assets representing 81.3% of total assets at 107.5B yen. The capital-intensive business model in waste processing and biomaterial production requires ongoing investment to maintain capacity, limiting free cash flow generation for debt reduction or shareholder returns. ROA of 4.4% indicates modest returns on the substantial asset base, and further asset growth without proportional profit acceleration would dilute returns.
[Industry Position] (Reference - Proprietary Analysis)
Furuhashi EPO demonstrates above-average profitability metrics relative to the IT and telecommunications industry peer group. Operating margin of 11.2% exceeds the industry median of 8.2% by 3.0 percentage points, ranking the company in the upper performance quartile. Net profit margin of 7.9% surpasses the industry median of 6.0% by 1.9 percentage points, confirming operational efficiency advantages. ROE of 10.0% outperforms the industry median of 8.3% by 1.7 percentage points, though this partially reflects higher financial leverage. ROA of 4.4% aligns closely with the industry median of 3.9%, indicating typical asset-based returns for the sector.
Financial health metrics present concerns relative to industry standards. Equity ratio of 44.3% trails the industry median of 59.2% by 14.9 percentage points, positioning the company in the lower stability quartile. Current ratio of 0.58x significantly underperforms the industry median of 2.15x, representing the most substantial deviation from peer norms and indicating elevated liquidity risk. Financial leverage of 2.25x exceeds the industry median of 1.66x, though remains within acceptable ranges.
Efficiency measures show mixed performance. Asset turnover of 0.56x lags the industry median of 0.67x by 16% due to the capital-intensive nature of waste management and biomaterial production relative to IT services. Revenue growth of 7.9% underperforms the industry median of 10.4%, though operating income growth of 10.2% demonstrates operational leverage. The company's working capital management as measured by negative working capital of 1.8B yen contrasts with industry norms, reflecting aggressive cash conversion at the expense of liquidity buffers.
Industry: Environmental Services and Waste Management (comparative data sourced from Proprietary Analysis across 104 companies in related sectors), Comparison basis: FY2025 Q3 period metrics, Source: Proprietary analysis of publicly disclosed financial data.
Core business strength with profitability above industry benchmarks: Operating margin of 11.2% and ROE of 10.0% both exceed industry medians, demonstrating competitive operational efficiency in the biomaterial and resource circulation businesses. The 10.2% operating profit growth outpacing 7.9% revenue growth indicates positive operating leverage and cost discipline, with the Biomaterial segment maintaining dominant market position at 72.8% of revenue.
Liquidity constraints requiring active financial management: Current ratio of 0.58x and cash-to-short-term-debt coverage of 0.46x represent material risks requiring immediate attention through debt restructuring or refinancing. The 81.1% increase in short-term borrowings to 22.7B yen creates refinancing pressure, though successful rollover and potential term extension to long-term facilities would normalize the capital structure. The company's ability to maintain bank relationships and access credit markets becomes a critical performance factor.
Divergence between operating and net income highlights non-operating factors: The "revenue up, operating profit up, but net income down" pattern is driven entirely by financial costs and prior-year comparisons rather than core business deterioration. Normalization of interest expenses and elimination of one-time factors would realign bottom-line growth with operating performance, suggesting current net income understates recurring earnings power. The company's forecast of 13.1% operating income growth for the full year indicates management confidence in business momentum despite near-term financial structure challenges.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.